* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Transient Overexpression of Recombinant Proteins in Mammalian
Survey
Document related concepts
Gene regulatory network wikipedia , lookup
Protein moonlighting wikipedia , lookup
Western blot wikipedia , lookup
Protein adsorption wikipedia , lookup
Cell-penetrating peptide wikipedia , lookup
List of types of proteins wikipedia , lookup
DNA vaccination wikipedia , lookup
Endogenous retrovirus wikipedia , lookup
Gene expression profiling wikipedia , lookup
Genomic library wikipedia , lookup
Silencer (genetics) wikipedia , lookup
Secreted frizzled-related protein 1 wikipedia , lookup
Two-hybrid screening wikipedia , lookup
Transcript
Transient Overexpression of Recombinant Proteins in Mammalian Cells pHEK293 Ultra Expression Vectors Ultrahigh expression of a protein of interest in HEK 293 cells Flexibility of a single or doublevector system Protein expression up to 10 times higher than with CMVderived promoters Ideal for production of biomedically relevant proteins, including monoclonal antibodies E. coli is commonly used to express recombinant proteins in life science research. However, mammalian cell based expression systems have several advantages over E. coli, especially for eukaryotic protein expression. Expression in mammalian cells allows for proper protein folding and posttranslational modification, features that are key for proper protein function in vitro. The pHEK293 Ultra Expression Vectors enable ultrahigh, transient overexpression of a protein of interest in human HEK 293 cells. Please visit our tech note for data specific to the use of these vectors for producing monoclonal antibodies. Principles of high expression with the TARTat system High levels of recombinant protein expression with the pHEK293 Ultra Expression Vectors is accomplished by a transcriptional activation mechanism based on the HIV1 virus TARTat system. The TAR (transactivation response) element is an RNA sequence derived from HIV1 that forms a stem loop structure at the 5' end of the viral RNA. Tat is an RNAbinding protein that binds to TAR and promotes transcription. pHEK293 Ultra Expression Vector I and Vector II systems incorporate the TARTat elements in order to provide ultrahigh expression of your protein of interest. Both Vector I and Vector II systems incorporate the TAR sequence in the 5' untranslated region of the target gene, where it will not affect the amino acid sequence of the expressed target protein. For the Vector I system, a Tat cassette is included on the same vector; the Vector II system includes the Tat cassette on a separate Enhancer Vector, enabling greater control of the protein of interest’s expression level. With both systems, expression of the Tat protein greatly increases the expression of the protein of interest. pHEK293 Ultra Expression Vector I (Cat. # 3390)—Obtain high expression with the convenience of a singleplasmid system pHEK293 Ultra Expression Vector II (Cat. # 3392)—Optimize expression levels by varying the ratio of Vector II and the included Enhancer Vector Schematic of protein overexpression using the pHEK293 Ultra Expression vector systems. The TAR element forms a stem loop structure at the 5' end of the transcribed RNA. Expression of the Tat element produces the Tat protein which binds to the TAR element in the RNA loop structure. This activates TAR, which in turn promotes high expression of your protein of interest. The cassette in the image above is from the singlevector system, where TAR and Tat are both on the same plasmid as your target gene, enabling more convenient transfection. In the twovector system, Tat is on a separate plasmid, allowing you to have control over expression levels by varying the ratio of the two vectors. Visualization of high expression using fluorescent proteins In order to assess protein expression capabilities, both pHEK293 Ultra Expression Vector systems were used to introduce a fluorescent protein (AcGFP1) into adherent and suspension HEK 293 cells. For comparison, the same assay was conducted with a vector expressing AcGFP1 from a CMV promoter (pBApoCMV DNA) and a high expression vector from Company A. Constructs were made by inserting AcGFP1 into the appropriate vectors (details listed in the table at the end of this page). Higher fluorescence intensity was observed for the pHEK293 systems (conditions 2, 3, and 4) than for either of the other two vectors (conditions 1 and 5). Additionally, a color change in suspension cells was readily apparent to the naked eye for cells transfected with the pHEK293 vectors. Visualization of AcGFP1 expression in adherent and suspension HEK 293 cells. Adherent cells (experimental conditions 1–5) were cultured in 12well plates. Suspension cells (experimental conditions 6–10) were cultured in 125ml flasks. Imaging was done two days posttransfection. Panel A. Fluorescent microscopy images (adherent cells). Panel B. Representative images of suspension cell cultures (condition 7 on the left; condition 10 on the right; conditions 6, 8, and 9 not shown). For Panels A and B, experimental conditions are as follows. Conditions 1 and 6: pBApoCMV; conditions 2 and 7: pHEK293 Ultra Expression Vector I; conditions 3 and 8: pHEK293 Ultra Expression Vector II + Enhancer Vector; conditions 4 and 9: same as 3 and 8, but with a larger amount of Enhancer Vector; conditions 5 and 10: Company A’s high expression vector. Quantitative data for all conditions are shown in the figure below. Flow cytometry was used to quantify the expression levels of AcGFP1 in adherent and suspension cells. Cells transfected with pHEK293 Ultra Expression Vector I (conditions 2 and 7) and pHEK293 Ultra Expression Vector II (conditions 3, 4, 8, and 9) displayed fluorescence intensities 5–11 times higher than that obtained with a typical CMV promoter (conditions 1 and 6), and 2–7 times higher than Company A’s highexpression vector (conditions 5 and 10). Additionally, cells transfected with the twovector system displayed an expected increase in AcGFP1 expression when the amount of Enhancer Vector was raised from 0.008 µg (condition 3) to 0.2 µg (condition 4) for adherent cells, and from 0.24 µg (condition 8) to 6 µg (condition 9) for suspension cells. Flow cytometry analysis of fluorescence intensity of AcGFP1 positive cells. AcGFP1 expression in adherent and suspension cells (transfected with constructs as described above) was quantified two days posttransfection. The table column directly below each bar on the graph lists the amount of each vector used in that specific experimental condition. Visit our antibody tech note for more data >> Visit the product page for pHEK293 Ultra Expression Vectors >> http://www.clontech.com/US/Products/Protein_Expression_and_Purification/Mammalian_Expression/ pHEK293_Ultra_Expression_Overview